GlassScriptPhysician profile
Sean B Holmes
NPI 1689649683
$17,511.37
in general payments reported to CMS, 2019-2025
56 companies · $2,201 in 2025
The $2,201 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,807 · 2020: $2,739 · 2021: $2,011 · 2022: $2,357 · 2023: $3,140 · 2024: $2,256 · 2025: $2,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,494 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,494.39 |
| Education | $102.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,682.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,616.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,467.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,420.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,181.39 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $1,001.90 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $973.14 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Pfizer INC. | $783.03 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $726.57 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $471.19 | 2019-2024 | Trintellix |
| Abbvie INC. | $440.29 | 2021-2025 | |
| Astellas Pharma US INC | $400.88 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $398.19 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $304.96 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $284.71 | 2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.